Cargando…

Development and Characterizations of Pullulan and Maltodextrin-Based Oral Fast-Dissolving Films Employing a Box–Behnken Experimental Design

Migraine is a neurological disorder characterized by severe headaches, visual aversions, auditory, and olfactory disorders, accompanied by nausea and vomiting. Zolmitriptan (ZMT(®)) is a potent 5HT1B/1D serotonin receptor agonist frequently used for the treatment of migraine. It has erratic absorpti...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Kiramat Ali, Gao, Binbin, Kamal, Robia, Razzaq, Anam, Qi, Sun, Zhu, Qiu-Ning, Lina, Song, Huang, Linyu, Cremin, Grainne, Iqbal, Haroon, Menaa, Farid, Cui, Jing-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146677/
https://www.ncbi.nlm.nih.gov/pubmed/35629620
http://dx.doi.org/10.3390/ma15103591
_version_ 1784716621526335488
author Shah, Kiramat Ali
Gao, Binbin
Kamal, Robia
Razzaq, Anam
Qi, Sun
Zhu, Qiu-Ning
Lina, Song
Huang, Linyu
Cremin, Grainne
Iqbal, Haroon
Menaa, Farid
Cui, Jing-Hao
author_facet Shah, Kiramat Ali
Gao, Binbin
Kamal, Robia
Razzaq, Anam
Qi, Sun
Zhu, Qiu-Ning
Lina, Song
Huang, Linyu
Cremin, Grainne
Iqbal, Haroon
Menaa, Farid
Cui, Jing-Hao
author_sort Shah, Kiramat Ali
collection PubMed
description Migraine is a neurological disorder characterized by severe headaches, visual aversions, auditory, and olfactory disorders, accompanied by nausea and vomiting. Zolmitriptan (ZMT(®)) is a potent 5HT1B/1D serotonin receptor agonist frequently used for the treatment of migraine. It has erratic absorption from the gastrointestinal tract (GIT), but its oral bioavailability is low (40–45%) due to the hepatic metabolism. This makes it an ideal candidate for oral fast dissolving formulations. Hence, the current study was undertaken to design and develop oral fast-dissolving films (OFDFs) containing ZMT for migraine treatment. The OFDFs were formulated by the solvent casting method (SCM) using Pullulan (PU) and maltodextrin (MDX) as film-forming agents and propylene glycol (PG) as a plasticizer. The strategy was designed using Box–Behnken experimental design considering the proportion of PU:MDX and percentage of PG as independent variables. The effectiveness of the OFDF’s was measured based on the following responses: drug release at five min, disintegration time (D-time), and tensile strength (TS). The influence of formulation factors, including percent elongation (%E), thickness, water content, moisture absorption, and folding endurance on ZMT-OFDFs, were also studied. The results showed a successful fabrication of stable ZMT-OFDFs, with surface uniformity and amorphous shape of ZMT in fabricated films. The optimized formulation showed a remarkable rapid dissolution, over 90% within the first 5 min, a fast D-time of 18 s, and excellent mechanical characteristics. Improved maximum plasma concentration (C max) and area under the curve (AUC 0–t) in animals (rats) treated with ZMT-OFDFs compared to those treated with an intra-gastric (i-g) suspension of ZMT were also observed. Copolymer OFDFs with ZMT is an exciting proposition with great potential for the treatment of migraine headache. This study offers a promising strategy for developing ZMT-OFDFs using SCM. ZMT-OFDFs showed remarkable rapid dissolution and fast D-time, which might endeavor ZMT-OFDFs as an auspicious alternative approach to improve patient compliance and shorten the onset time of ZMT in migraine treatment.
format Online
Article
Text
id pubmed-9146677
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91466772022-05-29 Development and Characterizations of Pullulan and Maltodextrin-Based Oral Fast-Dissolving Films Employing a Box–Behnken Experimental Design Shah, Kiramat Ali Gao, Binbin Kamal, Robia Razzaq, Anam Qi, Sun Zhu, Qiu-Ning Lina, Song Huang, Linyu Cremin, Grainne Iqbal, Haroon Menaa, Farid Cui, Jing-Hao Materials (Basel) Article Migraine is a neurological disorder characterized by severe headaches, visual aversions, auditory, and olfactory disorders, accompanied by nausea and vomiting. Zolmitriptan (ZMT(®)) is a potent 5HT1B/1D serotonin receptor agonist frequently used for the treatment of migraine. It has erratic absorption from the gastrointestinal tract (GIT), but its oral bioavailability is low (40–45%) due to the hepatic metabolism. This makes it an ideal candidate for oral fast dissolving formulations. Hence, the current study was undertaken to design and develop oral fast-dissolving films (OFDFs) containing ZMT for migraine treatment. The OFDFs were formulated by the solvent casting method (SCM) using Pullulan (PU) and maltodextrin (MDX) as film-forming agents and propylene glycol (PG) as a plasticizer. The strategy was designed using Box–Behnken experimental design considering the proportion of PU:MDX and percentage of PG as independent variables. The effectiveness of the OFDF’s was measured based on the following responses: drug release at five min, disintegration time (D-time), and tensile strength (TS). The influence of formulation factors, including percent elongation (%E), thickness, water content, moisture absorption, and folding endurance on ZMT-OFDFs, were also studied. The results showed a successful fabrication of stable ZMT-OFDFs, with surface uniformity and amorphous shape of ZMT in fabricated films. The optimized formulation showed a remarkable rapid dissolution, over 90% within the first 5 min, a fast D-time of 18 s, and excellent mechanical characteristics. Improved maximum plasma concentration (C max) and area under the curve (AUC 0–t) in animals (rats) treated with ZMT-OFDFs compared to those treated with an intra-gastric (i-g) suspension of ZMT were also observed. Copolymer OFDFs with ZMT is an exciting proposition with great potential for the treatment of migraine headache. This study offers a promising strategy for developing ZMT-OFDFs using SCM. ZMT-OFDFs showed remarkable rapid dissolution and fast D-time, which might endeavor ZMT-OFDFs as an auspicious alternative approach to improve patient compliance and shorten the onset time of ZMT in migraine treatment. MDPI 2022-05-18 /pmc/articles/PMC9146677/ /pubmed/35629620 http://dx.doi.org/10.3390/ma15103591 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shah, Kiramat Ali
Gao, Binbin
Kamal, Robia
Razzaq, Anam
Qi, Sun
Zhu, Qiu-Ning
Lina, Song
Huang, Linyu
Cremin, Grainne
Iqbal, Haroon
Menaa, Farid
Cui, Jing-Hao
Development and Characterizations of Pullulan and Maltodextrin-Based Oral Fast-Dissolving Films Employing a Box–Behnken Experimental Design
title Development and Characterizations of Pullulan and Maltodextrin-Based Oral Fast-Dissolving Films Employing a Box–Behnken Experimental Design
title_full Development and Characterizations of Pullulan and Maltodextrin-Based Oral Fast-Dissolving Films Employing a Box–Behnken Experimental Design
title_fullStr Development and Characterizations of Pullulan and Maltodextrin-Based Oral Fast-Dissolving Films Employing a Box–Behnken Experimental Design
title_full_unstemmed Development and Characterizations of Pullulan and Maltodextrin-Based Oral Fast-Dissolving Films Employing a Box–Behnken Experimental Design
title_short Development and Characterizations of Pullulan and Maltodextrin-Based Oral Fast-Dissolving Films Employing a Box–Behnken Experimental Design
title_sort development and characterizations of pullulan and maltodextrin-based oral fast-dissolving films employing a box–behnken experimental design
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146677/
https://www.ncbi.nlm.nih.gov/pubmed/35629620
http://dx.doi.org/10.3390/ma15103591
work_keys_str_mv AT shahkiramatali developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT gaobinbin developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT kamalrobia developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT razzaqanam developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT qisun developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT zhuqiuning developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT linasong developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT huanglinyu developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT cremingrainne developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT iqbalharoon developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT menaafarid developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign
AT cuijinghao developmentandcharacterizationsofpullulanandmaltodextrinbasedoralfastdissolvingfilmsemployingaboxbehnkenexperimentaldesign